TL;DR: Hyperbaric oxygen therapy (HBOT) is a licensed medical device therapy in Canada. Health Canada regulates the chambers, not a defined indication list, so clinical use is guided primarily by the Undersea and Hyperbaric Medical Society (UHMS) recognised indications. Referring physicians may recommend HBOT off-label when clinical judgment and the available evidence support it, but the medical-legal footing changes sharply once you step outside the UHMS-recognised list. This guide explains how to document, consent, and refer responsibly.
HBOT off-label use in Canada is a routine part of hyperbaric practice. Registry data show roughly 4 percent of cases are treated for non-recognised conditions, and referrals for long COVID, traumatic brain injury, radiation cystitis, and calciphylaxis continue to grow. For Canadian referring physicians, the question is rarely whether off-label HBOT is permitted. It is how to protect the patient, the chart, and your licence when you recommend it.
What does “off-label” actually mean for HBOT in Canada?
Off-label HBOT refers to any hyperbaric treatment delivered for a condition that is not on the recognised conditions list. In drug regulation, “off-label” has a precise meaning tied to the Health Canada product monograph. Medical-device therapy is different. Health Canada licences hyperbaric chambers as Class III medical devices under the Medical Devices Regulations, but it does not publish a condition-specific indication list the way the U.S. FDA does. That leaves Canadian clinicians operating inside a framework set by three sources:
- Health Canada approves the chamber and its intended use (delivery of oxygen at increased ambient pressure for medical purposes).
- UHMS and CUHMA define the clinically recognised indications and publish the evidence-based protocols most Canadian hyperbaric programs follow.
- Provincial colleges of physicians and surgeons set the standard of care for individual referring and supervising physicians.
When you refer a patient for an indication that falls inside the UHMS list, you are on well-travelled ground. When you refer for anything outside it, you are making an off-label clinical judgment that requires additional documentation and consent.
Which indications are considered “on-label” for HBOT?
The recognised conditions, current to the 15th edition, form the reference list used by most Canadian hospitals and regulated facilities. For a deeper dive, see our 2026 UHMS referral guide. The current recognised indications are:
- Air or gas embolism
- Carbon monoxide poisoning (including cyanide)
- Clostridial myositis and myonecrosis (gas gangrene)
- Crush injury, compartment syndrome, and other acute traumatic ischemias
- Decompression sickness
- Arterial insufficiencies (including central retinal artery occlusion and enhancement of healing in selected problem wounds)
- Severe anaemia
- Intracranial abscess
- Necrotizing soft tissue infections
- Refractory osteomyelitis
- Delayed radiation injury (soft tissue and bony necrosis)
- Compromised grafts and flaps
- Acute thermal burn injury
- Idiopathic sudden sensorineural hearing loss
- Avascular necrosis (idiopathic femoral head necrosis)
Any condition not on this list is considered off-label by Canadian hyperbaric programs, even when regional data or recent randomised trials suggest benefit.
Is off-label HBOT legal in Canada?
Yes. Off-label use of an approved medical device or drug is a long-standing feature of Canadian medical practice, provided the physician exercises clinical judgment, documents rationale, and obtains informed consent. The Canadian Medical Protective Association (CMPA) has repeatedly confirmed that off-label prescribing is not in itself unlawful or unethical. The legal risk arises from three places: inadequate consent, poor documentation, and failure to meet the provincial college’s standard of care.
How common is off-label HBOT in real-world practice?
According to the International Multicentre Registry for Hyperbaric Oxygen Therapy, which captured 2,880 patients across 22 participating centres through June 2021, 125 patients (roughly 4.3 percent) were treated for non-recognised conditions (Harlan NP et al, Undersea Hyperb Med, 2022, PMID 36001560 (PubMed)). The registry reported quality-of-life gains and low complication rates across both approved and unapproved groups. Canadian contribution to this registry is small but growing.
What are the most common off-label indications Canadian physicians ask about?
Based on referral patterns across Canadian hospitals and regulated facilities, the most frequently requested off-label indications are:
| Indication | Evidence level | Typical referral source |
|---|---|---|
| Persistent post-concussion syndrome / mild TBI | Multiple RCTs, mixed results | Neurology, family medicine |
| Long COVID / post-viral fatigue | Small RCTs, emerging | Internal medicine, GP |
| Fibromyalgia | Systematic review, low-moderate | Rheumatology, pain clinic |
| Radiation cystitis beyond standard approval | Observational, moderate | Urology |
| Chronic Lyme and post-treatment Lyme | Low-quality, inconsistent | Infectious disease, ID |
| Autism spectrum disorder | Meta-analysis, contested | Developmental paediatrics |
| Inflammatory bowel disease | Growing RCT evidence | Gastroenterology |
The evidence base varies widely. Chronic brain injury, for example, has failed to show benefit in several sham-controlled trials, and leading hyperbaric physicians caution against systematic off-label use in this population (Mitchell SJ, Bennett MH, Diving Hyperb Med, 2014, PMID 25596836 (PubMed)). Inflammatory bowel disease, by contrast, has accumulating RCT data suggesting real effect in refractory ulcerative colitis.
How should I document an off-label HBOT referral?
Documentation is the single most important piece of medical-legal protection for any off-label referral. The chart entry should include:
- The specific condition being treated and why standard therapies have failed or are inappropriate.
- A summary of the evidence reviewed, citing at least one peer-reviewed source.
- Explicit acknowledgment that the indication is not UHMS-recognised.
- The treatment plan: expected number of sessions, pressure profile, and endpoints for re-assessment.
- Informed consent discussion: benefits, risks, alternatives, and the patient’s understanding that outcomes are uncertain.
- Coverage status: whether the patient is paying privately, using extended health benefits, or pursuing provincial coverage (most provinces do not cover off-label HBOT).
Does provincial health insurance cover off-label HBOT?
Generally, no. Provincial plans such as OHIP, MSP, AHCIP, RAMQ, MSI, Medicare NB, and MCP fund HBOT only for recognised conditions delivered in hospitals and regulated facilities. Off-label HBOT is almost always delivered in private regulated facilities and paid out of pocket or by private insurance. This has two practical consequences for referring physicians:
- Patients should be told explicitly that coverage is unlikely before you send the referral.
- The chart should reflect that coverage was discussed, to prevent later disputes.
Our provincial coverage guide details which indications are funded by each provincial plan.
What consent elements are specific to off-label HBOT?
Standard informed-consent elements apply, with three additions:
- Indication status: the patient must understand the condition is not on the UHMS recognised list.
- Evidence quality: describe whether the evidence is supported by RCTs, systematic reviews, or observational data only.
- Financial exposure: the patient must understand the likely cost and that provincial coverage does not apply.
CMPA guidance emphasises that consent for any off-label intervention should be documented in the physician’s own words rather than a generic form, with the specific risks and unknowns noted in the chart.
Should I refer to a hospital program or a private regulated facility?
It depends on the indication. Hospital hyperbaric programs (Toronto General, Vancouver General, HSC Winnipeg, Centre hospitalier universitaire de Sherbrooke, Moncton, and others) are funded by provincial ministries and generally only accept on-label referrals. For most off-label indications, the referral pathway is to a private regulated facility. Canada now has 33 hyperbaric facilities across 9 provinces, 11 of which are hospital-based. Use our directory of Canadian hospitals and regulated facilities to confirm which accept off-label referrals and at what cost.
When is off-label HBOT contraindicated even with consent?
Absolute contraindications apply equally to on-label and off-label HBOT:
- Untreated pneumothorax
- Concurrent use of bleomycin, cisplatin, doxorubicin, or disulfiram
- Untreated severe obstructive airway disease
- Claustrophobia without premedication plan
- Unstable cardiac disease or decompensated heart failure
For off-label cases, a higher threshold is reasonable. When an indication lacks strong evidence and the patient has significant relative contraindications, declining to refer is often the safer clinical and medical-legal choice.
What about mild or low-pressure “HBOT” chambers?
Low-pressure soft-sided chambers operating at 1.3 ATA do not deliver the oxygen partial pressures used in UHMS-recognised therapy. Recent transcutaneous oximetry data found average tissue oxygen values of 161 mmHg at 1.4 ATA versus 333 mmHg at 2.0 ATA, p less than 0.001 (Sack RA et al, Undersea Hyperb Med, 2024, PMID 38615347 (PubMed)). Patients often confuse the two. When a referral request mentions a specific home or wellness-studio chamber, clarify that any evidence cited in the UHMS guidelines applies to medical-grade hyperbaric oxygen, not mild hyperbaric air.
How should I communicate off-label risk to the patient?
The Undersea and Hyperbaric Medical Society and the CMPA share a common theme: be honest about uncertainty. A reasonable script includes:
“This condition is not on the list of indications the hyperbaric society has approved based on strong evidence. Some recent studies show possible benefit, others do not. I can send a referral so you can discuss it with a hyperbaric physician. The treatment is likely safe, but we cannot promise it will work, and provincial coverage will not apply.”
Documenting that this conversation happened, in the patient’s own language where possible, is more protective than any generic waiver.
Frequently asked questions
Can I be disciplined for referring off-label?
Not for the referral itself, provided it reflects clinical judgment, evidence review, and documented consent. Disciplinary action typically follows failures in one of those three areas, not the fact of off-label use.
Do I need a special form for off-label referrals?
No. A standard referral letter is acceptable. Many hyperbaric programs provide their own intake form and will not proceed without documented physician sign-off that the patient understands the off-label status.
Does the CMPA cover me for off-label HBOT referrals?
CMPA assistance generally extends to members who follow accepted standards of care and document their reasoning. Members with questions about specific referrals can contact CMPA directly before proceeding.
How many treatments does off-label HBOT typically involve?
Most off-label protocols run 20 to 60 sessions at 1.5 to 2.4 ATA. The hyperbaric physician sets the exact protocol after their own assessment.
Should I try HBOT before more conventional therapies?
No. Off-label HBOT should be considered only after reasonable first-line and second-line treatments have failed, unless specific evidence supports earlier use in a given condition.
Can I refer a patient for HBOT directly, or does it need a specialist?
Family physicians can refer directly in every Canadian province. Some hyperbaric programs prefer referrals to come from the specialist managing the underlying condition, particularly for neurological or oncological indications.
How do I stay current on changing indications?
UHMS publishes indication updates every three to five years. CUHMA tracks Canadian developments. Our research library indexes more than 14,400+ HBOT studies and is updated nightly.
Practical referral checklist
- Confirm indication status against the UHMS list
- Review at least one peer-reviewed source on the specific condition
- Document conservative and standard therapies already tried
- Screen for absolute contraindications
- Discuss cost and coverage; document the discussion
- Obtain and chart informed consent in the patient’s own language
- Select a Canadian hospital or regulated facility accepting off-label referrals
- Communicate expected duration and re-assessment points
- Arrange follow-up to evaluate response and adverse events
Finding a qualified Canadian hyperbaric program
Canada Hyperbarics maintains an independent, continuously verified list of hospitals and regulated facilities across the country. Every facility is cross-referenced against CUHMA membership, provincial licensing records, and chamber accreditation data. For off-label referrals in particular, use our national facility directory to identify programs willing to accept your referral and to confirm current pricing, wait times, and protocol capabilities. Canada Hyperbarics does not operate any hyperbaric facility and receives no compensation from listed clinics.
Bottom line
Off-label HBOT referrals are a legitimate and often necessary part of Canadian clinical practice. The legal and professional footing is secure when the referring physician documents clinical rationale, reviews the evidence, obtains informed consent, discloses coverage limitations, and selects an appropriate Canadian hospital or regulated facility. When these elements are in place, off-label referral is medicine as it has always been practised: careful, evidence-informed, and grounded in the patient’s consent.
This content is for informational purposes only and does not constitute medical advice or legal advice. Referring physicians should consult their provincial college, the CMPA, and current UHMS guidelines before acting on any specific referral.